Comparative study of cilnidipine loaded PLGA nanoparticles: process optimization by DoE, physico-chemical characterization and in vivo evaluation
Authors:
- 23 April 2020
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 10 (5) , 1442-1458
Abstract
Cilnidipine (CND) is known to have low oral bioavailability due to its poor aqueous solubility, low dissolution rate, and high gut wall metabolism. In the present study, CND-loaded PLGA nanoparticles (CND-PLGA-NPs) were prepared with two different grades of PLGA (50:50 and 75:25) by design of experiment. Critical factors affecting particle size and entrapment efficiency (EE%) were assessed by mixed design approach, comprising of Plackett-Burman design followed by rotatable central composite design. Particle size, PDI, zeta potential, and EE% of optimized formulations of CND-PLGA(50:50)-NPs and CND-PLGA(75:25)-NPs were 211.6 ± 1.8 nm, 0.21 ± 0.05, − 15.1 ± 1.6 mV, and 85.9 ± 1.5% and 243.5 ± 2.4 nm, 0.23 ± 0.06, −19.6 ± 1.3 mV, and 92.0 ± 1.2% respectively. No significant changes were observed in physical stability of NPs when stored at 25 °C/60% RH over a period of 3 months. Pharmacokinetic studies revealed that Fabs of CND-PLGA(50:50)-NPs (1.15) and CND-PLGA(75:25)-NPs (2.23) were significantly higher than the free CND (0.26). The Cmax and AUC0-∞ of CND-PLGA(50:50)-NPs (787.42 ± 27.38 ng/mL and 9339.37 ± 252.38 ng/ml × h) and CND-PLGA(75:25)-NPs (803.49 ± 19.63 ng/mL and 18,153.34 ± 543.05 ng/ml × h) were significantly higher (p ˂ 0.0001) compared with free CND (367.69 ± 47.22 ng/mL and 2107.95 ± 136.40 ng/ml × h). MRTOral of CND-PLGA(50:50)-NPs (33.36 ± 0.48 h) and CND-PLGA(75:25)-NPs (48.37 ± 0.61 h) were significantly higher (p ˂ 0.0001) compared with free CND (4.69 ± 0.58 h). CND-PLGA-NPs can provide higher and sustained plasma drug levels of CND and be effective in antihypertensive therapy. Graphical abstractKeywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology (DST-INSPIRE-IF150457)
This publication has 34 references indexed in Scilit:
- Preparation and evaluation of cilnidipine microemulsionJournal of Pharmacy and Bioallied Sciences, 2012
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhancedin vitroanti-tumor activityBiomedical Materials, 2010
- Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman designInternational Journal of Pharmaceutics, 2010
- PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distributionInternational Journal of Pharmaceutics, 2008
- PLA/PLGA nanoparticles for sustained release of docetaxelInternational Journal of Pharmaceutics, 2006
- Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issuesAAPS PharmSciTech, 2005
- The preparation of monodisperse biodegradable polyester nanoparticles with a controlled sizeJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2003
- Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation methodBiomaterials, 2001
- Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertensionBritish Journal of Clinical Pharmacology, 2000